Mesoblast (NASDAQ:MESO) Shares Cross Below 50-Day Moving Average – Time to Sell?

Mesoblast Limited (NASDAQ:MESO) passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $17.19 and traded as low as $15.02. Mesoblast shares last traded at $15.07, with a volume of 129,446 shares traded.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Mesoblast in a report on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy”.

Mesoblast Stock Down 3.6%

The company has a debt-to-equity ratio of 0.10, a current ratio of 1.58 and a quick ratio of 1.41. The business has a fifty day moving average of $17.19 and a 200-day moving average of $16.87. The stock has a market cap of $1.94 billion, a PE ratio of -17.13 and a beta of 2.17.

Mesoblast (NASDAQ:MESO) last released its quarterly earnings data on Thursday, January 29th. The company reported ($0.16) earnings per share (EPS) for the quarter. The firm had revenue of $25.67 million for the quarter. Equities research analysts anticipate that Mesoblast Limited will post -0.7 earnings per share for the current year.

Hedge Funds Weigh In On Mesoblast

Hedge funds have recently modified their holdings of the stock. Goldman Sachs Group Inc. acquired a new stake in Mesoblast in the 1st quarter worth approximately $3,209,000. Creative Planning acquired a new stake in shares of Mesoblast during the second quarter worth $141,000. Raymond James Financial Inc. purchased a new stake in shares of Mesoblast during the second quarter valued at $86,000. China Universal Asset Management Co. Ltd. increased its position in shares of Mesoblast by 33.7% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 9,124 shares of the company’s stock valued at $99,000 after acquiring an additional 2,302 shares during the period. Finally, Farther Finance Advisors LLC purchased a new position in Mesoblast in the 3rd quarter worth $58,000. Institutional investors and hedge funds own 1.43% of the company’s stock.

Mesoblast Company Profile

Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective.

The company’s most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn’s disease.